Charlotte Robinson

DocwireNews

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist approved for use in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage renal disease (ESRD), cardiovascular death, nonfatal myocardial infarction, and hospitalization due to heart failure. Two years after its approval, researchers led by <a href="https://www.docwirenews.com/post/findings-on-daprodustat-dosing-and-finerenone-utilization">Ajay Singh </a>studied the drug&rsquo;s utilization. They presented results at the National Kidney Foundation Spring Clinical Meetings.Their observational, cross-sectional study examined patients who were prescribed finerenone between August 2021 and September 2023 and had 12 months of electronic health record activity prior to their first prescription date (index). Patient data came from practices across all 50 states and nearly 15% of US ambulatory care centers.The study included 20,535 patients; mean age was 68 years, 44.3% were female, and 44.8% were White. Of patients with both eGFR and urine albumin-to-creatinine ratio lab results (n=4320), 71.1% had values that fell into the categories of high risk or very high risk according to Kidney Disease Improving Global Outcomes (KDIGO) standards. The percentage of patients with prescriptions for sodium-glucose cotransporter inhibitors, glucagon-like peptide-1 receptor agonists, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers was 40.5%, 29.0%, 23.7%, and 38.4%, respectively.The proportion of patients prescribed finerenone by primary care physicians, nephrologists, endocrinologists, and cardiologists was 40.9%, 17.4%, 10.7%, and 8.8%, respectively; 82.8% received an initial dose of 10 mg. Despite being recommended by KDIGO and the American Diabetes Association, finerenone was highly underutilized, with the lowest utilization in the Midwest. The study authors believe future studies &ldquo;should compare CKD in T2D patients with versus without finerenone, as well as associated outcomes.&rdquo;Source: Singh A, Singh R, Du Y, et al. <a href="https://doi.org/10.1053/j.ajkd.2024.01.337" target="_blank" rel="noopener">Utilization of nonsteroidal MRA finerenone: evaluation of real-world data in the United States, 2021-2023.</a> Presented at the National Kidney Foundation Spring Clinical Meetings 2024; May 14-18, 2024; Long Beach, California.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Utilization of Finerenone by Patients With T2D, CKD

NKF Spring Clinical Meetings 2024

Two years after its approval, researchers studied the use of finerenone in adults with type 2 diabetes and chronic kidney disease (CKD).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe